Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.41 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3791900 | 0.99 | MAPT (0.47) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL3791891 | 0.88 | MAPT (0.45) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL23786318 | 0.86 | MAPT (0.47) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL23705193 | 0.85 | KMT2A (0.55) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL21113593 | 0.85 | KMT2A (0.55) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL28845231 | 0.85 | KMT2A (0.55) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL23786301 | 0.82 | ALDH1A1 (0.48) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL20402644 | 0.79 | MAPT (0.57) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL23705089 | 0.79 | MAPT (0.57) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL21531212 | 0.79 | MAPT (0.52) | MAPTKDM4EALDH1A1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827624-B2 | Covalent immune recruiter compounds for immune cell recognition and associated uses | MCMASTER UNIVERSITY (CA) | 2023-11-28 | — | — | US | disclosed |
| US-11827624-B2 | Covalent immune recruiter compounds for immune cell recognition and associated uses | MCMASTER UNIVERSITY (CA) | 2023-11-28 | — | — | US | disclosed |
| US-20210276981-A1 | COVALENT IMMUNE RECRUITER COMPOUNDS FOR IMMUNE CELL RECOGNITION AND ASSOCIATED USES | MCMASTER UNIVERSITY (CA) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827624-B2 | Covalent immune recruiter compounds for immune cell recognition and associated uses | CD74, CD4, HLA-A | MAPT 875/4885KDM4E 3145/4885ALDH1A1 396/4885 |
| US-20210276981-A1 | COVALENT IMMUNE RECRUITER COMPOUNDS FOR IMMUNE CELL RECOGNITION AND ASSOCIATED USES | CD74, CD4, HLA-A | MAPT 1211/4885KDM4E 3686/4885ALDH1A1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.